Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

No longer available 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 1Expanded_access 1

Sponsor

Cancer Type

Tumor-Agnostic 2

Conditions

Solid Tumors Harboring NTRK Fusion 2Neoplasm Metastasis 2

Interventions

pembrolizumab 156Gemcitabine 140Capecitabine 123Paclitaxel 120Fluorouracil 117Oxaliplatin 110Bevacizumab 106Nivolumab 99Leucovorin 97Docetaxel 97Cisplatin 89Radiosurgery 88Irinotecan 87Carboplatin 85Cetuximab 72Cyclophosphamide 71Magnetic Resonance Spectroscopy 68Specimen Handling 60Radiotherapy 60Trastuzumab 59Biopsy 59Ipilimumab 53Drug Therapy 51Everolimus 48Pemetrexed 46Albumin-Bound Paclitaxel 45130-nm albumin-bound paclitaxel 44Doxorubicin 42Fulvestrant 40aldesleukin 37

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Neoplasm Metastasis × selitrectinib × Clear all
NCT03215511 2024-10-30

A Study to Test the Safety of the Investigational Drug Selitrectinib in Children and Adults That May Treat Cancer

Bayer

Phase 1 Completed
81 enrolled
Tumor-Agnostic

Neoplasm Metastasis

NCT03206931 2021-09-16

Expanded Access to Provide Selitrectinib for the Treatment of Cancers With a NTRK Gene Fusion

Bayer

No longer available
Tumor-Agnostic

Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡